{
    "clinical_study": {
        "@rank": "154686", 
        "arm_group": [
            {
                "arm_group_label": "Sodium Alginate Double Action Tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily"
            }, 
            {
                "arm_group_label": "Matching placebo tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo tablets, 2 tablets four times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to provide evidence that Compound Sodium Alginate Double\n      Action Chewable Tablets are effective in managing the symptoms of heartburn, acid\n      regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD)."
        }, 
        "brief_title": "Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Gastroesophageal Reflux Disease", 
            "Dyspepsia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current evidence of symptomatic GERD in accord with the Montreal definition\n\n          -  Patients must have had troublesome heartburn and/or regurgitation (with or without\n             dyspepsia symptoms) of at least mild or moderate intensity on at least five days\n             during the week before the start of screening\n\n        Exclusion Criteria:\n\n          -  Patients who have a history of drug, solvent or alcohol abuse\n\n          -  Patients who have suffered cardiac chest pain within the last year.\n\n          -  Patients who have suffered a recent, significant unexplained weight loss of more than\n             6 Kg in the last 6 months.\n\n          -  Female patients of childbearing potential who, for the duration of the study, are\n             either unwilling or unable to take adequate contraceptive precautions or are\n             unwilling to be sexually abstinent\n\n          -  Pregnancy or lactating mother.\n\n          -  Patients with a history and/or symptom profile and/or discovered on endoscopy\n             suggestive of the following:  any other gastrointestinal (GI) disease, erosive GERD\n             (Los Angeles [LA] classification grades C-D), Barrett's esophagus, acute peptic ulcer\n             and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric\n             stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious\n             anaemia, indication for H-pylori eradication therapy, known gastro-intestinal\n             bleeding (hematochezia or hematemesis) within the last 3 months, and severe diseases\n             of other major body systems.\n\n          -  Patients who were observed on endoscopy to have a hiatus hernia with a diameter which\n             exceeds 3cm.\n\n          -  Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for\n             treating gastrointestinal disease, ulcermin or misoprostol preparations within 7 days\n             prior to screening or throughout the study.\n\n          -  Patients who have taken PPIs during the 10 days prior to screening, prokinetics or H2\n             antagonists during the 5 days prior to screening or systemic glucocorticosteroids,\n             non-steroidal anti-inflammatory drugs (NSAIDs, except for low dose aspirin which can\n             be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or\n             quadruple therapy for eradication of H-pylori during the last 28 days.\n\n          -  Patients taking or requiring to take macrolide antibiotics, such as erythromycin,\n             azithromycin, from the day before screening.\n\n          -  Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.\n\n          -  Patients with severe constipation, or history of intestinal obstruction.\n\n          -  In the opinion of the Investigator, patients with damaged heart or kidney diseases\n             and patients who require a low sodium diet.\n\n          -  Any previous history of allergy or known intolerance to any of the IMP's"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1107", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869491", 
            "org_study_id": "GA1210"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sodium Alginate Double Action Tablets", 
                "description": "2 tablets four times daily", 
                "intervention_name": "Compound Sodium Alginate Double Action Chewable Tablets", 
                "intervention_type": "Drug", 
                "other_name": "Gaviscon Double Action Tablets"
            }, 
            {
                "arm_group_label": "Matching placebo tablets", 
                "description": "2 tablets four times daily", 
                "intervention_name": "Matching placebo tablets", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alginic acid", 
                "Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastroesophageal Reflux Disease", 
            "GERD", 
            "Dyspepsia", 
            "Indigestion", 
            "Heartburn", 
            "Acid reflux", 
            "Compound Sodium Alginate Double Action Chewable Tablets", 
            "Gaviscon Double Action Tablets"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "RB Investigational Sites"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "RB Investigational Sites"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease", 
        "overall_official": {
            "affiliation": "Shanghai Jiaotong University, School of Medicine, Shanghai, China", 
            "last_name": "Yuan Yaozong, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary study endpoint is to compare the change from baseline in RDQ symptom scores for the GERD dimension (heartburn and regurgitation) after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo", 
            "measure": "Change from baseline in GERD dimension", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Comparison between the two cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) for a 7-day treatment period for change from baseline in RDQ scores for dyspepsia dimension", 
            "measure": "Change from baseline in RDQ scores for dyspepsia dimension", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "source": "Reckitt Benckiser Healthcare (UK) Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Healthcare (UK) Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}